Annals of the Russian academy of medical sciencesAnnals of the Russian academy of medical sciencesВестник Российской академии медицинских наук0869-60472414-3545"Paediatrician" Publishers LLC220710.15690/vramn2207ONCOLOGY: CURRENT ISSUESАКТУАЛЬНЫЕ ВОПРОСЫ ОНКОЛОГИИReview Article99mTc-Labelled Low Molecular Weight Inhibitors of Prostate-Specific Membrane AntigenМеченные технецием-99m низкомолекулярные ингибиторы простат-специфического мембранного антигенаhttps://orcid.org/0000-0001-8983-59762724-0930TishchenkoViktoriia K.ТищенкоВиктория Константиновна
Russian Federation

PhD in Biology

д.б.н.

vikshir82@mail.ruhttps://orcid.org/0000-0002-0231-21773769-6210PetrievVasily M.ПетриевВасилий Михайлович
Russian Federation

PhD in Biology

д.б.н.

petriev@mrrc.obninsk.ruhttps://orcid.org/0000-0001-5170-95952554-3985VlasovaOksana P.ВласоваОксана Петровна
Russian Federation

PhD in Biology

к.б.н.

somina@inbox.ruhttps://orcid.org/0000-0001-7291-97435463-3790PankratovAndrei A.ПанкратовАндрей Александрович
Russian Federation

PhD in Biology

к.б.н.

andreimnioi@yandex.ruhttps://orcid.org/0000-0002-7159-805X1286-6518MorozovaNatalia B.МорозоваНаталья Борисовна
Russian Federation

PhD in Biology

к.б.н.

n.b.morozova@yandex.ruhttps://orcid.org/0000-0001-8901-45966849-3221ShegaiPetr V.ШегайПетр Викторович
Russian Federation

MD, PhD

к.м.н.

dr.shegai@mail.ruhttps://orcid.org/0000-0001-7689-60324264-5167IvanovSergei A.ИвановСергей Анатольевич
Russian Federation

MD, PhD, Professor, Corresponding Member of the RAS

д.м.н., профессор, член-корреспондент РАН

oncourolog@gmail.comhttps://orcid.org/0000-0001-8784-84151759-8101KaprinAndrei D.КапринАндрей Дмитриевич
Russian Federation

MD, PhD, Professor, Academician of the RAS

д.м.н., профессор, академик РАН

kaprin@mail.ruA. Tsyb Medical Radiological Research CentreМедицинский радиологический научный центр им. А.Ф. ЦыбаNational Research Nuclear University MEPHI (Moscow Engineering Physics Institute)Национальный исследовательский ядерный университет «МИФИ»National Medical Research Radiological CentreНациональный медицинский исследовательский центр радиологииP.A. Hertsen Moscow Oncology Research InstituteМосковский научный исследовательский онкологический институт имени П.А. ГерценаRUDN UniversityРоссийский университет дружбы народов25122022040220237764204361109202209122022Copyright ©; 2023, "Paediatrician" Publishers LLCCopyright ©; 2023, Издательство "Педиатръ"2023"Paediatrician" Publishers LLCИздательство "Педиатръ"https://vestnikramn.spr-journal.ru/jour/article/view/2207

High morbidity and mortality rates of prostate cancer (PCa) determine the requirement of looking for new methods of its early diagnosis. Methods of nuclear medicine have a special place in addressing this problem as they allow functional, metabolic and other processes imaging in body, which occur during the cancer development. This approach supposes the use of radiopharmaceuticals (RP), which are capable of selective binding to a specific biological target, for example, prostate-specific membrane antigen (PSMA), which is known to be overexpressed in PCa. Current development of new radiotracers for PCa imaging is focused on low molecular weight PSMA inhibitors due to their high specific binding to PSMA and rapid urinary excretion. Technetium-99m remains the appropriate radionuclide for diagnostic studies due to its optimal nuclear properties, ease of production and versatile coordination chemistry. Therefore, single-photon emission computed tomography (SPECT) imaging with 99mTc-PSMA radioligands can be a cost effective alternative to PET with 68Ga- or 18F-labeled RP. The aim of this review is to summarize and analyze currently available data on 99mTc-labeled low molecular weight PSMA inhibitors for metastatic PCa imaging.

Особое место в ранней диагностике заболеваемости раком предстательной железы (РПЖ) занимают методы ядерной медицины, которые позволяют визуализировать функциональные, метаболические и иные процессы в организме, возникающие при наличии онкологического процесса. Благодаря высокоспецифичному связыванию с простат-специфическим мембранным антигеном (ПСМА) и быстрому выведению из организма с мочой именно низкомолекулярные ингибиторы ПСМА доминируют при разработке новых радиоиндикаторов для визуализации РПЖ. Технеций-99m остается наиболее подходящим радионуклидом для диагностических исследований благодаря своим оптимальным физико-химическим свойствам и удобству получения. В связи с этим однофотонная эмиссионная компьютерная томография (ОФЭКТ) с радиолигандами к ПСМА, меченными 99mTc, может быть экономически выгодной альтернативой ПЭТ с препаратами на основе 68Ga или 18F. Цель данного обзора — обобщить и проанализировать имеющиеся на сегодняшний день данные о меченных 99mTc низкомолекулярных ингибиторах ПСМА, предназначенных для визуализации метастатического РПЖ.

prostate-specific membrane antigen PSMAtechnetium-99mlow molecular weight PSMA inhibitorsprostate cancersingle-photon emission computed tomographyпростат-специфический мембранный антиген ПСМАтехнеций-99mнизкомолекулярные ингибиторы ПСМАрак предстательной железыоднофотонная эмиссионная компьютерная томографияМинистерство здравоохранения Российской ФедерацииMinistry of Health of the Russian FederationGlobal Cancer Observatory. Available from: https://gco.iarc.fr (accessed: 12.04.2022).Состояние онкологической помощи населению России в 2020 году / под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. — М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2021. — 239 с. [Sostoyanie onkologicheskoj pomoshchi naseleniyu Rossii v 2020 godu / pod red. AD Kaprina, VV Starinskogo, AO Shahzadovoj. Moscow: MNIOI im. P.A. Gercena — filial FGBU “NMIC radiologii” Minzdrava Rossii; 2021. 239 s. (In Russ.)]Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2021;79(2):243–262. doi: https://doi.org/10.1016/j.eururo.2020.09.042Xu X, Zhang J, Hu S, et al. 99mTc-labeling and evaluation of a HYNIC modified small-molecular inhibitor of prostate-specific membrane antigen. Nucl Med Biol. 2017;48:69–75. doi: https://doi.org/10.1016/j.nucmedbio.2017.01.010Walker SM, Lim I, Lindenberg L, et al. Positron emission tomography (PET) radiotracers for prostate cancer imaging. Abdom Radiol (NY). 2020;45(7):2165–2175. doi: https://doi.org/10.3390/ijms23095023Stott Reynolds TJ, Smith CJ, Lewis MR. Peptide-Based Radiopharmaceuticals for Molecular Imaging of Prostate Cancer. Adv Exp Med Biol. 2018;1096:135–158. doi: https://doi.org/10.1007/978-3-319-99286-0_8Kuppermann D, Calais J, Marks LS. Imaging Prostate Cancer: Clinical Utility of Prostate-Specific Membrane Antigen. J Urol. 2022; 207(4):769–778. doi: https://doi.org/10.1097/JU.0000000000002457Леонтьев А.В., Халимон А.И., Кулиев М.Т., и др. Современные возможности применения радиофармпрепаратов на основе лигандов к простатспецифическому мембранному антигену, меченных 99mTc, при раке предстательной железы // Онкоурология. — 2021. — Т. 17. — № 4. — С. 136–150. [Leontyev AV, Khalimon AI, Kuliev MT, et al. Modern possibilities of application 99mTc-labeled prostate-specific membrane antigen ligands in prostate cancer. Onkourologiya = Cancer Urology. 2021;17(4):136–150. (In Russ.)] doi: https://doi.org/10.17650/1726-9776-2021-17-4-136-150Duatti A. Review on 99mTc radiopharmaceuticals with emphasis on new advancements. Nucl Med Biol. 2021;92:202–216. doi: https://doi.org/10.1016/j.nucmedbio.2020.05.005Gourni E, Henriksen G. Metal-Based PSMA Radioligands. Molecules. 2017;22(4):523. doi: https://doi.org/10.3390/molecules22040523Brunello S., Salvarese N, Carpanese D, et al. A Review on the Current State and Future Perspectives of [99mTc]Tc-Housed PSMA-i in Prostate Cancer. Molecules. 2022;27(9):2617. doi: https://doi.org/10.3390/molecules27092617Czerwińska M, Bilewicz A, Kruszewski M, et al. Targeted Radionuclide Therapy of Prostate Cancer — From Basic Research to Clinical Perspectives. Molecules. 2020;25(7):1743. doi: https://doi.org/10.3390/molecules25071743Mattias J, Engelhardt J, Schäfer M, et al. Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies. Cancer Res. 2021;81(8):2234–2245. doi: https://doi.org/10.1158/0008-5472.CAN-20-1624Kopka K, Benešova M, Barinka C, et al. Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers. J Nucl Med. 2017;58(Suppl 2):17S–26S. doi: https://doi.org/10.2967/jnumed.116.186775Марук А.Я., Брускин А.Б., Кодина Г.Е. Новые радиофармпрепараты на основе 99mTc с применением бифункциональных хелатирующих агентов // Радиохимия. — 2011. — Т. 53. — № 4. — С. 289–300. [Maruk AYa, Bruskin AB, Kodina GE. Novel 99mTc radiopharmaceuticals with bifunctional chelating agents. Radiochemistry. 2011;53(4):341–353. (In Russ.)]. doi: https://doi.org/10.1134/S1066362211040011Banerjee SR, Foss CA, Castanares M, et al. Synthesis and Evaluation of Technetium-99m- and Rhenium-Labeled Inhibitors of the Prostate-Specific Membrane Antigen (PSMA). J Med Chem. 2008;51(15):4504–4517. doi: https://doi.org/10.1021/jm800111uBanerjee SR, Pullambhatla M, Foss CA, et al. Effect of Chelators on the Pharmacokinetics of 99mTc-Labeled Imaging Agents for the Prostate-Specific Membrane Antigen (PSMA). J Med Chem. 2013;56(15):6108–6121. doi: https://doi.org/10.1021/jm400823wLu G, Maresca KP, Hillier SM, et al. Synthesis and SAR of 99mTc/Re-Labeled Small Molecule Prostate Specific Membrane Antigen Inhibitors with Novel Polar Chelates. Bioorg Med Chem Lett. 2013;23(5):1557–1563. doi: https://doi.org/10.1016/j.bmcl.2012.09.014Hillier SM, Maresca KP, Lu G, et al. 99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate Cancer. J Nucl Med. 2013;54(8):1369–1376. doi: https://doi.org/10.2967/jnumed.112.116624Kimura H, Sampei S, Matsuoka D, et al. Development of 99mTc-labeled asymmetric urea derivatives that target prostate-specific membrane antigen for single-photon emission computed tomography imaging. Bioorg Med Chem. 2016;24(10):2251–2256. doi: https://doi.org/10.1016/j.bmc.2016.03.051Lodhi NA, Park JY, Kim K, et al. Synthesis and Evaluation of 99mTc-Tricarbonyl Labeled Isonitrile Conjugates for Prostate-Specific Membrane Antigen (PSMA) Image. Inorganics. 2020;8(1):5. doi: https://doi.org/10.3390/inorganics8010005Xiao D, Duan X, Gan Q, et al. Preparation and Biological Evaluation of [99mTc]Tc-CNGU as a PSMA-Targeted Radiotracer for the Imaging of Prostate Cancer. Molecules. 2020;25(23):5548. doi: https://doi.org/10.3390/molecules25235548Kularatne SA, Zhou Z, Yang J, et al. Design, Synthesis, and Preclinical Evaluation of Prostate-Specific Membrane Antigen Targeted 99mTc-Radioimaging Agents. Mol Pharm. 2009;6(3):790–800. doi: https://doi.org/10.1021/mp9000712Robu S, Schottelius M, Eiber M, et al. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer. J Nucl Med. 2017;58(2):235–242. doi: https://doi.org/10.2967/jnumed.116.178939Rauscher I, Duwel C, Wirtz M, et al. Value of 111In-prostate-specific membrane antigen (PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: Correlation with histopathology and clinical follow-up. BJU Int. 2017;120(1):40–47. doi: https://doi.org/10.1111/bju.13713Jilg CA, Reichel K, Stoykow C, et al. Results from extended lymphadenectomies with [111In]PSMA-617 for intraoperative detection of PSMA-PET/CT-positive nodal metastatic prostate cancer. EJNMMI Res. 2020;10(1):17. doi: https://doi.org/10.1186/s13550-020-0598-2Ferro-Flores G, Luna-Gutierrez M, Ocampo-Garcia B, et al. Clinical translation of a PSMA inhibitor for 99mTc-based SPECT. Nucl Med Biol. 2017;48:36–44. doi: https://doi.org/10.1016/j.nucmedbio.2017.01.012Mosayebnia M, Hajimahdi Z, Beiki D, et al. Design, Synthesis, Radiolabeling and Biological Evaluation of New Urea-Based Peptides Targeting Prostate Specific Membrane Antigen. Bioorg Chem. 2020;99:103743. doi: https://doi.org/10.1016/j.bioorg.2020.103743Sikora AE, Maurin M, Jaron AW, et al. PSMA Inhibitor Derivatives for Labelling with 99mTc via HYNIC, a Radiopharmaceutical Kit, Radiopharmaceutical Preparations and Their Use in Prostate Cancer Diagnostics. Bulletin Number EP3721907A1. European Patent; 2020.Vats K, Agrawal K, Sharma R, et al. Preparation and clinical translation of 99mTc-PSMA-11 for SPECT imaging of prostate cancer. Medchemcomm. 2019;10(12):2111–2117. doi: https://doi.org/10.1039/c9md00401gVallabhajosula S, Nikolopoulou A, Babich JW, et al. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer. J Nucl Med. 2014;55(11):1791–1798. doi: https://doi.org/10.2967/jnumed.114.140426Goffin KE, Joniau S, Tenke P, et al. Phase 2 study of 99mTc-Trofolastat SPECT/CT to identify and localize prostate cancer in intermediate- and high-risk patients undergoing radical prostatectomy and extended pelvic LN dissection. J Nucl Med. 2017;58(9):1408– 1413. doi: https://doi.org/10.2967/jnumed.116.187807Schmidkonz C, Cordes M, Beck M, et al. SPECT/CT with the PSMA Ligand 99mTc-MIP-1404 for Whole-Body Primary Staging of Patients With Prostate Cancer. Clin Nucl Med. 2018;43(4):225–231. doi: https://doi.org/10.1097/RLU.0000000000001991Schmidkonz C, Atzinger A, Goetz TI, et al. 99mTc-MIP-1404 SPECT/CT for Patients with Metastatic Prostate Cancer: Interobserver and Intraobserver Variability in Treatment-Related Longitudinal Tracer Uptake Assessments of Prostate-Specific Membrane Antigen-Positive Lesions. Clin Nucl Med. 2020;45(2):105–112. doi: https://doi.org/10.1097/RLU.0000000000002880Schmidkonz C, Hollweg C, Beck M, et al. 99mTc-MIP-1404-SPECT/CT for the Detection of PSMA-Positive Lesions in 225 Patients with Biochemical Recurrence of Prostate Cancer. Prostate. 2018;78(1):54–63. doi: https://doi.org/10.1002/pros.23444Reinfelder J, Kuwert T, Beck M, et al. First Experience with SPECT/CT Using a 99mTc-Labeled Inhibitor for Prostate-Specific Membrane Antigen in Patients with Biochemical Recurrence of Prostate Cancer. Clin Nucl Med. 2017;42(1):26–33. doi: https://doi.org/10.1097/RLU.0000000000001433Schmidkonz C, Götz TI, Atzinger A, et al. 99mTc-MIP-1404 SPECT/CT for Assessment of Whole-Body Tumor Burden and Treatment Response in Patients with Biochemical Recurrence of Prostate Cancer. Clin Nucl Med. 2020;45(8):e349–e357. doi: https://doi.org/10.1097/RLU.0000000000003102Schmidkonz C, Goetz TI, Kuwert T, et al. PSMA SPECT/ CT with 99mTc-MIP-1404 in Biochemical Recurrence of Prostate Cancer: Predictive Factors and Efficacy for the Detection of PSMA-Positive Lesions at Low and Very-Low PSA Levels. Ann Nucl Med. 2019;33(12):891–898. doi: https://doi.org/10.1007/s12149-019-01400-6Schmidkonz C, Cordes M, Beck M, et al. Assessment of Treatment Response by 99mTc-MIP-1404 SPECT/CT: A Pilot Study in Patients with Metastatic Prostate Cancer. Clin Nucl Med. 2018;43(8):e250–e258. doi: https://doi.org/10.1097/RLU.0000000000002162Ellis WJ, Donnelly BJ, Gorin MA, et al. PD60-11 phase 3 study to evaluate the safety and efficacy of 99mTc-MIP-1404 SPECT/CT imaging to detect clinically significant prostate cancer in men with biopsy proven low grade prostate cancer who are candidates for active surveillance (PROSPECT-AS). J Urol. 2019;201(Suppl4):e1100. doi: https://doi.org/10.1097/01.JU.0000557222.99762.6bMaurer T, Robu S, Schottelius M, et al. 99mTechnetium-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate Cancer. Eur Urol. 2019;75(4):659–666. doi: https://doi.org/10.1016/j.eururo.2018.03.013Mix M, Schultze-Seemann W, von Büren M, et al. 99mTc-Labelled PSMA Ligand for Radio-Guided Surgery in Nodal Metastatic Prostate Cancer: Proof of Principle. EJNMMI Res. 2021;11(1):22. doi: https://doi.org/10.1186/s13550-021-00762-1Horn T, Kronke M, Rauscher I, et al. Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer. Eur Urol. 2019;76(4):517–523. doi: https://doi.org/10.1016/j.eururo.2019.03.045Werner P, Neumann C, Eiber M, et al. [99cmTc]Tc-PSMA-I&S-SPECT/CT: Experience in prostate cancer imaging in an outpatient center. EJNMMI Res. 2020;10(1):45. doi: https://doi.org/10.1186/s13550-020-00635-zAlbalooshi B, Al Sharhan M, Bagheri F, et al. Direct Comparison of 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT in Patients with Prostate Cancer. Asia Ocean J Nucl Med Biol. 2020;8(1):1–7. doi: https://doi.org/10.22038/aojnmb.2019.43943.1293Urbán S, Meyer C, Dahlbom M, et al. Radiation Dosimetry of 99mTc-PSMA I&S: A Single-Center Prospective Study. J Nucl Med. 2021;62(8):1075–1081. doi: https://doi.org/10.2967/jnumed.120.253476Santos-Cuevas C, Davanzo J, Ferro-Flores G, et al. 99mTc-labeled PSMA inhibitor: Biokinetics and radiation dosimetry in healthy subjects and imaging of prostate cancer tumors in patients. Nucl Med Biol. 2017;52:1–6. doi: https://doi.org/10.1016/j.nucmedbio.2017.05.005Lawal IO, Ankrah AO, Mokgoro NP, et al. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: a comparative analysis with Ga-68 PSMA PET/CT. Prostate. 2017;77(11):1205–1212. doi: https://doi.org/10.1002/pros.23379García-Pérez FO, Davanzo J, López-Buenrostro S, et al. Head to Head Comparison Performance of 99mTc-EDDA/HYNIC-IPSMA SPECT/CT and 68Ga-PSMA-11 PET/CT a Prospective Study in Biochemical Recurrence Prostate Cancer Patients. Am J Nucl Med Mol Imaging. 2018;8(5):332–340.Fallahi B, Khademi N, Karamzade-Ziarati N, et al. 99mTc-PSMA SPECT/CT Versus 68Ga-PSMA PET/CT in the Evaluation of Metastatic Prostate Cancer. Clin Nucl Med. 2021;46(2):e68–e74. doi: https://doi.org/10.1097/RLU.0000000000003410Kabunda J, Gabela L, Kalinda C, et al. Comparing 99mTc-PSMA to 99mTc-MDP in Prostate Cancer Staging of the Skeletal System. Clin Nucl Med. 2021;46(7):562–568. doi: https://doi.org/10.1097/RLU.0000000000003702Vallejo-Armenta P, Soto-Andonaegui J, Villanueva-Pérez RM, et al. [99mTc]Tc-IPSMA SPECT Brain Imaging as a Potential Specific Diagnosis of Metastatic Brain Tumors and High-Grade Gliomas. Nucl Med Biol. 2021;96–97:1–8. doi: https://doi.org/10.1016/j.nucmedbio.2021.02.003Liu C, Zhu Y, Su H, et al. Relationship between PSA Kinetics and Tc-99m HYNIC PSMA SPECT/CT Detection Rates of Biochemical Recurrence in Patients with Prostate Cancer after Radical Prostatectomy. Prostate. 2018;78(16):1215–1221. doi: https://doi.org/10.1002/pros.23696Su HC, Zhu Y, Ling GW, et al. Evaluation of 99mTc-Labeled PSMA-SPECT/CT Imaging in Prostate Cancer Patients Who Have Undergone Biochemical Relapse. Asian J Androl. 2017;19(3):267–271. doi: https://doi.org/10.4103/1008-682X.192638Su H, Zhu Y, Hu S, et al. The Value of 99mTc-PSMA SPECT/CT-Guided Surgery for Identifying and Locating Lymph Node Metastasis in Prostate Cancer Patients. Ann Surg Oncol. 2019;26(2):653–659. doi: https://doi.org/10.1245/s10434-018-6805-yLi P, Liu C, Wu S, et al. Combination of 99mTc-Labeled PSMA-SPECT/CT and Diffusion-Weighted MRI in the Prediction of Early Response after Carbon Ion Therapy in Prostate Cancer: A Non-Randomized Prospective Pilot Study. Cancer Manag Res. 2021;13:2191–2199. doi: https://doi.org/10.2147/CMAR.S285167Ćwikła JB, Roslan M, Skoneczna I, et al. Initial Experience of Clinical Use of [99mTc]Tc-PSMA-T4 in Patients with Prostate Cancer. A Pilot Study. Pharmaceuticals (Basel). 2021;14(11):1107. doi: https://doi.org/10.3390/ph14111107Sergieva S, Mangaldgiev R, Dimcheva M, et al. SPECT-CT Imaging with [99mTc]PSMA-T4 in Patients with Recurrent Prostate Cancer. Nucl Med Rev Cent East Eur. 2021;24(2):70–81. doi: https://doi.org/10.5603/NMR.2021.0018Singh B, Sharma S, Bansal P, et al. Comparison of the Diagnostic Utility of 99mTc-PSMA Scintigraphy versus 68Ga-PSMA-11 PET/CT in the Detection of Metastatic Prostate Cancer and Dosimetry Analysis: A Gamma-Camera-Based Alternate Prostate-Specific Membrane Antigen Imaging Modality. Nucl Med Commun. 2021;42(5):482–489. doi: https://doi.org/10.1097/MNM.0000000000001361